NasdaqGS:NH

Stock Analysis Report

Executive Summary

NantHealth, Inc., together with its subsidiaries, operates as a healthcare technology company in the United States and internationally.

Snowflake

Fundamentals

Slightly overvalued with concerning outlook.


Similar Companies

Share Price & News

How has NantHealth's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.2%

NH

-1.5%

US Healthcare Services

1.0%

US Market


1 Year Return

-49.0%

NH

16.4%

US Healthcare Services

8.0%

US Market

Return vs Industry: NH underperformed the US Healthcare Services industry which returned 16.4% over the past year.

Return vs Market: NH underperformed the US Market which returned 8% over the past year.


Shareholder returns

NHIndustryMarket
7 Day4.2%-1.5%1.0%
30 Day-3.6%-3.7%-0.07%
90 Day40.6%-6.6%-1.0%
1 Year-49.0%-49.0%16.6%16.4%10.4%8.0%
3 Year-94.1%-94.1%64.0%63.4%46.2%36.7%
5 Yearn/a63.2%61.7%64.3%46.2%

Price Volatility Vs. Market

How volatile is NantHealth's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NantHealth undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NH ($0.77) is trading below our estimate of fair value ($9.91)

Significantly Below Fair Value: NH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NH is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: NH is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NH has negative assets, so we can't compare its PB Ratio to the US Healthcare Services industry average.


Next Steps

Future Growth

How is NantHealth forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

43.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NH is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NH is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NH is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NH's revenue (11.7% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: NH's revenue (11.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NH is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has NantHealth performed over the past 5 years?

-17.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: NH is unprofitable, and losses have increased over the past 5 years at a rate of -17.2% per year.

Accelerating Growth: Unable to compare NH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-1.2%).


Return on Equity

High ROE: NH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: NH is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: NH is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is NantHealth's financial position?


Financial Position Analysis

Short Term Liabilities: NH has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: NH has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: NH has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: NH's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: NH has a low level of unsold assets or inventory.

Debt Coverage by Assets: NH has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NH has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if NH has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is NantHealth's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate NH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if NH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of NantHealth's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average management tenure


CEO

Patrick Soon-Shiong (66yo)

9.3yrs

Tenure

0

Dr. Patrick Soon-Shiong, M.D., FRCS (C), FACS, MBBCh, MSc, FRCS (C), is an Owner of Los Angeles Times Communications, LLC. Dr. Soon-Shiong is a physician, surgeon and scientist, invented and developed the  ...


Management Age and Tenure

2.0yrs

Average Tenure

54yo

Average Age

Experienced Management: NH's management team is considered experienced (2 years average tenure).


Board Age and Tenure

3.4yrs

Average Tenure

67yo

Average Age

Experienced Board: NH's board of directors are considered experienced (3.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Patrick Soon-Shiong (66yo)

    Founder

    • Tenure: 9.3yrs
  • Ron Louks (54yo)

    COO & Director

    • Tenure: 1.3yrs
    • Compensation: US$718.53k
  • Bobby Reddy

    Chief Medical Officer

    • Tenure: 2.4yrs
  • Brandon Villery

    VP, General Counsel & Corporate Secretary

    • Tenure: 2yrs
  • Keith Krebs

    Senior Vice President of Client Services

    • Tenure: 2yrs
  • Chris House

    Senior Vice President of Product Development

    • Tenure: 2yrs
  • Maureen Becker

    Vice President of Human Resources

    • Tenure: 1.7yrs
  • Bob Petrou (47yo)

    Chief Financial Officer

    • Tenure: 1.1yrs
    • Compensation: US$490.43k
  • Mark Mozley

    Senior VP of Global Sales & Marketing

    • Tenure: 1.8yrs

Board Members

  • Patrick Soon-Shiong (66yo)

    Founder

    • Tenure: 9.3yrs
  • Michael Blaszyk (67yo)

    Director

    • Tenure: 3.4yrs
    • Compensation: US$248.80k
  • Kirk Calhoun (75yo)

    Director

    • Tenure: 3.4yrs
    • Compensation: US$240.05k
  • Michael Sitrick (72yo)

    Director

    • Tenure: 3.4yrs
    • Compensation: US$246.30k
  • Ron Louks (54yo)

    COO & Director

    • Tenure: 1.3yrs
    • Compensation: US$718.53k

Company Information

NantHealth, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NantHealth, Inc.
  • Ticker: NH
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$85.187m
  • Shares outstanding: 110.63m
  • Website: https://nanthealth.com

Number of Employees


Location

  • NantHealth, Inc.
  • 9920 Jefferson Boulevard
  • Culver City
  • California
  • 90232
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NHNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJun 2016
NELDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2016

Biography

NantHealth, Inc., together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 00:47
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.